Department of Surgery, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Department of Pathology, Austin Health, Heidelberg, VIC, Australia.
BMC Res Notes. 2023 Jan 27;16(1):7. doi: 10.1186/s13104-022-06268-w.
After liver transplant (LT), many investigations are needed to evaluate abnormal liver function test (LFT), which has poor specificity for graft function and complication. A single center retrospective audit of all adult single organ LT from 1/1/2015 to 31/12/2017 was performed. Demographic, clinical and investigation data from the LT database and electronic medical records and cost data from the hospital's Business Intelligence Unit were analyzed. Patients were classified into uncomplicated or complicated LFT by 2 independent investigators and the number, type, and cost of investigations in the first 30 post-operative days were analyzed. Investigations prior to liver biopsy was sub-analyzed.
There was 170 LT with 87 cases of uncomplicated LFT (51.2%) and 83 cases of complicated LFT (48.8%). Most patients with complicated LFT had additional investigations (97.6%), most commonly cholangiogram (55.4%) and liver biopsy (LBx) (50.6%). The additional investigations cost was $1863.3 (95% CI 1289.0-2437.6). Although most LBx (73.8%) showed evidence of rejection, LBx was often not the initial investigation of choice. Current LFT based post-transplant monitoring is inefficient. It remains difficult to determine which patient will benefit from an early invasive procedure like LBx, using LFT alone without further imaging investigations.
肝移植(LT)后,许多检查都需要评估异常肝功能试验(LFT),其对移植物功能和并发症的特异性较差。对 2015 年 1 月 1 日至 2017 年 12 月 31 日所有成人单器官 LT 的单一中心回顾性审核进行了评估。分析了 LT 数据库和电子病历中的人口统计学、临床和调查数据以及医院商业智能部门的成本数据。由 2 名独立调查员将患者分为无并发症或有并发症 LFT,并分析术后 30 天内的检查数量、类型和成本。对肝活检前的检查进行了亚分析。
共有 170 例 LT,其中 87 例无并发症 LFT(51.2%),83 例有并发症 LFT(48.8%)。大多数有并发症 LFT 的患者进行了额外的检查(97.6%),最常见的是胆管造影(55.4%)和肝活检(LBx)(50.6%)。额外检查的费用为 1863.3 美元(95%CI 1289.0-2437.6)。尽管大多数 LBx(73.8%)显示有排斥反应的证据,但 LBx通常不是最初的检查选择。目前基于 LFT 的移植后监测效率低下。仅使用 LFT 而不进行进一步的影像学检查,仍然难以确定哪些患者将受益于 LBx 等早期侵袭性手术。